Abstract
Background: Accumulating evidence suggests that CD62L and CD106 are positively expressed on the surface of mesenchymal stem cells (MSCs). It has been reported that both receptors can be induced by tumor necrosis factor- (TNF-?), granulocyte-colony stimulating factor (G-CSF), and vascular endothelial growth factor (VEGF) on leucocytes. However, whether these stimulations induce CD62L and CD106 expressions on MSCs is still unknown. Thus, in the present study we investigated the effects of TNF-?, G-CSF and VEGF on CD62L and CD160 expressions on the surface of MSCs. Method: MSCs were isolated from rat bone marrows, and treated with different concentrations of TNF- ? (0.1, 1 and 10 ng/mL), G-CSF and VEGF (1, 10, and 100 ng/mL) for 12 and 24 hours respectively. Then the expressions of CD62L and CD106 on the surface of MSCs were analyzed by flow cytometry. Results: Immunochemistry assay showed positive CD90 but negative CD45 in the MSCs. Flow cytometry analysis suggested that TNF-? and G-CSF could induce CD62L and CD106 expressions on the surface of MSCs in a dose-dependent manner, but not in a time-dependent manner. Further, all the concentrations of VEGF had no significant effect on the CD62L and CD106 expressions. Conclusion: CD62L and CD106 can be induced by TNF-? and G-CSF on the surface of MSCs, but not by VEGF. These findings can help improve BM-MSC migration capability and therapeutic efficiencies of MSC transplantation. Keywords: CD106, CD62L, G-CSF, mesenchymal stem cells, TNF-?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.